Thirty years after the discovery of cystic fibrosis, researchers have developed a new therapy that is expected to improve the condition of 90 percent of the cystic fibrosis population. Last October, the U.S. Food and Drug Administration expedited the approval of Trikafta (elexacaftor/ivacaftor/tezacaftor), a triple combination therapy licensed by Vertex Pharmaceuticals.